The Impact of Online Networks and Big Data in Life Sciences


Advances in Information Technology (IT) have enhanced our ability to gather, collect and analyze information from individuals and specific groups of people online. The emergence of online networks has facilitated connections between individuals by leveraging data exchange in a variety of fields. Online networking in life sciences transforms data collection into actionable information that will improve individual and population health, deliver effective therapies and, consequently, reduce the cost of healthcare. These novel tools might also have a direct impact in personalized medicine programs, since the adoption of new products by health care professionals in life sciences and peer-to-peer learning could be improved using social networks and big data analytics. However, one of the main concerns of information exchange online is data privacy. In this article, we will review how online networks and big data analytics are impacting the life sciences sector.

Share and Cite:

Gujarathi, R. and F. Costa, F. (2014) The Impact of Online Networks and Big Data in Life Sciences. Social Networking, 3, 58-64. doi: 10.4236/sn.2014.31007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. Standage, “Social Networking in the 1600s,” New York Times, 2013.
[2] A. Mitchell, T. Rosenstiel and L. Christian, “Mobile Devices and News Consumption: Some Good Signs for Journalism|State of the Media,” The State of the News Media 2013.
[3] R. Cachia, “Social Computing?: Study on the Use and Impact of Online Social Networking,” 2008.
[4] S. Terry and P. Terry, “Power to the People: Participant Ownership of Clinical Trial Data,” Science Translational Medicine, Vol. 3, No. 69, 2011, pp. 1-4.
[5] “Definition and Benefits of Electronic Medical Records (EMR)|Providers & Professionals|,” The Official Site for Health IT Information, 2013.
[6] Reuters, “Hospitals Speed Transition to Electronic Medical Records, Study Says,” Breaking News and Opinion on the Huffington Post, 2013.
[7] M. P. Coutinho and F. F. Costa, “Social Media in Science and Medicine,” G.I.T. Laboratory Journal, Vol. 7, 2011, pp. 10-12.
[8] F. F. Costa, “Big Data in Biomedicine,” Drug Discovery Today, 2013, in Press.
[9] K. Miller, “Big Data Analytics in Biomedical Research,” Biomedical Computation Review, 2012, pp. 14-21.
[10] B. Malin, K. El Emam and C. O’Keefe, “Biomedical Data Privacy: Problems, Perspectives, and Recent Advances,” Journal of the American Medical Informatics Association, Vol. 20, No. 1, 2013, pp. 2-7.
[11] K. Mandl and I. Kohane, “Escaping the EHR Trap—The Future of Health IT,” New England Journal of Medicine, Vol. 366, 2012, pp. 2240-2242.
[12] M. E. Frisse, K. B. Johnson, H. Nian, C. L. Davison, C. S. Gadd, et al., “The Financial Impact of Health Information Exchange on Emergency Department Care,” Journal of the American Medical Informatics Association, Vol. 10, 2011, pp. 1-6.
[13] F. F. Costa, L. S. Foly and M. P. Coutinho, “DataGenno: Building a New Tool to Bridge Molecular and Clinical Genetics,” The Application of Clinical Genetics, Vol. 4, 2011, pp. 45-54.
[14] F. F. Costa, “Social Networks, Web-Based Tools and Diseases: Implications for Biomedical Research,” Drug Discovery Today, Vol. 18, No. 5-6, 2013, pp. 272-281.
[15] W. T. Kerr, E. P. Lau and G. E. Owens, “The Future of Medical Diagnostics: Large Digitized Databases,” Yale Journal of Biology and Medicine, Vol. 85, No. 3, 2012, pp. 363-377.
[16] Pricewaterhouse Coopers, “Joining the Conversation: Life Science Industry Ventures into Social Media Despite Regulatory Uncertainty,” Knowledge Line, 2011.
[17] S. Blank, “Why the Lean Start-Up Changes Everything,” Harvard Business Review, 2013.
[18] T. C. Norman, C. Bountra, A. M. Edwards, K. R. Yamamoto and S. H. Friend, “Leveraging Crowd Sourcing to Facilitate the Discovery of New Medicines,” Science Translational Medicine, Vol. 3, No. 88, 2011, p. 88.
[19] M. Anderson, “No Time to Waste,” Science Translational Medicine, Vol. 5, 2013.
[20] P. Keckley and M. Hoffmann, “Social Networks in Health Care: Communication, Collaboration and Insights,” Deloitte, 2010.
[21] T. Hisey, C. Franck and M. Hoffmann, “To Friend or Not?? New Insights about Social Networks in the Life Sciences Industry,” Deloitte, 2010.
[22] L. Thompson, et al., “Protected Health Information on Social Networking Sites: Ethical and Legal Considerations,” Journal of Medical Internet Research, Vol. 13, No. 1, 2011, p. e8.
[23] S. Terry and P. Terry, “Power to the People: Participant Ownership of Clinical Trial Data,” Science Translational Medicine, Vol. 3, No. 69, 2011, pp. 1-4.
[24] V. A. Fusaro, P. Patil, E. Gafni, D. P. Wall and P. J. Tonellato, “Biomedical Cloud Computing with Amazon Web Services,” PLoS Computational Biology, Vol. 7, No. 8, 2011, Article ID: e1002147.
[25] “Personalized Medicine,” US News & World Report, 2011.
[26] F. F. Costa, “Genomics, Epigenomics and Personalized Medicine,” BioForum Europe, 2009, pp. 2-4.
[27] ACMG Board of Directors, “Points to Consider in the Clinical Application of Genomic Sequencing,” Genetics in Medicine, Vol. 14, No. 8, 2012, pp. 759-761.
[28] M. Najafzadeh, L. D. Lynd, J. C. Davis, S. Bryan, A. Anis, M. Marra and C. A. Marra, “Barriers to Integrating Personalized Medicine into Clinical Practice: A Best- Worst Scaling Choice Experiment,” Genetics in Medicine, Vol. 14, No. 5, 2012, pp. 520-526.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.